Multiple myeloma survivor creates angels as a token of comfort for patients

Seated at her craft table in her Creswell home, Debbie Luttrell labors over the beadwork in front of her. At one time, her crafting was constructing necklaces and headdresses. But these days, her focus is on creating angels. It's a project of love that began after Debbie faced one of the darkest days of her life.

By | March 28th, 2018|Blog, Targeting Cancer|

Support services available locally for cancer survivors

Cancer can take a tremendous toll-physically, emotionally and financially. Fortunately, there is a network of local services that patients can tap into to find support. "Every patient is different; everybody's journey is different. Someone might need a particular resource at one point, whereas another person might need the same resource at a different point," says Katie Burke, a patient navigator at Willamette Valley Cancer Institute.

Telegenetics offer patients a look at their inheritable cancer risk

Genevieve White wants to know more about her family tree. And for good reason: many of her relatives on her mother's side of the family have developed some type of cancer. "I'm the first one in three generations of my family to survive colon cancer," Genevieve says. "I want to know what's going on, mostly for the sake of the next generations, like my nieces and my nephews." Genetics and cancer risk Most cancer cases [...]

Cutting-edge therapies give melanoma patients more options

The National Cancer Institute estimates that more than 87,000 new cases of melanoma were diagnosed in 2017. While not as common as other forms of skin cancer, melanoma is more aggressive, and if it's not diagnosed and treated early, it can spread rapidly to other organs. Within the last 10 years, however, researchers have developed new treatments that are giving patients hope.

By | January 2nd, 2018|Blog, Melanoma, Targeting Cancer|

Clinical trials offer patients access to the latest breakthroughs

When Shari Pimental underwent routine surgery two years ago to remove her gallbladder, she woke up in the recovery room and learned she had stage III ovarian cancer.

Dr. Kathleen Yang, Shari's gynecologic oncologist at Willamette Valley Cancer Institute, thought Shari could possibly benefit from a clinical trial at WVCI for an investigational drug, classified as a PARP inhibitor that's designed to block specific enzymes that cancer cells need to survive.

By | December 20th, 2017|Blog, Clinical Trials, Targeting Cancer|
Load More Posts